Published in Mol Cell Biol on December 01, 1992
Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature (2009) 8.70
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature (2008) 6.04
Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol (2002) 4.77
The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A (2005) 3.72
Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol Biol Cell (2001) 3.59
A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol (2002) 2.66
Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc Natl Acad Sci U S A (1996) 2.66
p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol (2005) 2.65
p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev (1998) 2.53
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A (2000) 2.49
A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell (2010) 2.47
p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol (1999) 2.41
The role of nuclear lamin B1 in cell proliferation and senescence. Genes Dev (2011) 2.38
c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev (1999) 2.31
Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol Cell Biol (2007) 2.25
Btf, a novel death-promoting transcriptional repressor that interacts with Bcl-2-related proteins. Mol Cell Biol (1999) 2.22
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A (2011) 2.14
Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol (1994) 2.12
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J (2007) 2.07
Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell (2010) 1.95
Role of Stat3 in regulating p53 expression and function. Mol Cell Biol (2005) 1.91
Transformation of human and murine fibroblasts without viral oncoproteins. Mol Cell Biol (2005) 1.81
Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes. EMBO J (1993) 1.77
The p400 E1A-associated protein is a novel component of the p53 --> p21 senescence pathway. Genes Dev (2005) 1.70
p53 domains: structure, oligomerization, and transformation. Mol Cell Biol (1994) 1.68
Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO J (1994) 1.64
Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J (1999) 1.63
Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol (1998) 1.62
The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. Mol Syst Biol (2005) 1.60
Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol (1994) 1.54
Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res (1993) 1.49
Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol Cell Biol (1995) 1.43
Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol Cell Biol (1993) 1.42
Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain. EMBO J (1998) 1.39
SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal (2009) 1.35
Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J (1996) 1.34
Abolition of cyclin-dependent kinase inhibitor p16Ink4a and p21Cip1/Waf1 functions permits Ras-induced anchorage-independent growth in telomerase-immortalized human fibroblasts. Mol Cell Biol (2003) 1.32
Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J (2001) 1.32
Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proc Natl Acad Sci U S A (1996) 1.31
Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol (1994) 1.30
Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol Cell Biol (1999) 1.30
Lamin B1 fluctuations have differential effects on cellular proliferation and senescence. J Cell Biol (2013) 1.28
TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. J Cell Physiol (2010) 1.27
Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation. EMBO J (1993) 1.25
Zbtb4 represses transcription of P21CIP1 and controls the cellular response to p53 activation. EMBO J (2008) 1.23
The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc Natl Acad Sci U S A (1995) 1.22
Arrest of mammalian fibroblasts in G1 in response to actin inhibition is dependent on retinoblastoma pocket proteins but not on p53. J Cell Biol (2003) 1.22
Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia (2011) 1.17
Surveillance mechanism linking Bub1 loss to the p53 pathway. Proc Natl Acad Sci U S A (2007) 1.17
p90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling. J Biol Chem (2009) 1.16
Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired hetero-oligomerization. Proc Natl Acad Sci U S A (1999) 1.15
Interference with p53 protein inhibits hematopoietic and muscle differentiation. J Cell Biol (1996) 1.15
Nuclear factor of activated T-cells isoform c4 (NFATc4/NFAT3) as a mediator of antiapoptotic transcription in NMDA receptor-stimulated cortical neurons. J Neurosci (2009) 1.11
Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53. Mol Cell Biol (2001) 1.10
Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. J Virol (2004) 1.10
Analysis of a protein-binding domain of p53. Mol Cell Biol (1993) 1.10
Novel mutants of NAB corepressors enhance activation by Egr transactivators. EMBO J (1998) 1.10
Inhibition of nucleolar transcription as a trigger for neuronal apoptosis. J Neurochem (2008) 1.06
p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells. Mol Cell Biol (1996) 1.06
Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-kappaB activation. EMBO J (1997) 1.05
A mouse mammary epithelial cell model to identify molecular mechanisms regulating breast cancer progression. Methods Enzymol (2008) 1.05
v-Src generates a p53-independent apoptotic signal. Mol Cell Biol (2000) 1.04
Direct involvement of p53 in programmed cell death of oligodendrocytes. EMBO J (1995) 1.04
Overexpression of c-Myc alters G(1)/S arrest following ionizing radiation. Mol Cell Biol (2002) 1.04
The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region. Nucleic Acids Res (1996) 1.02
Resistance of mitochondrial p53 to dominant inhibition. Mol Cancer (2008) 1.01
Human cancer-associated mutations in the Aα subunit of protein phosphatase 2A increase lung cancer incidence in Aα knock-in and knockout mice. Mol Cell Biol (2011) 1.00
Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3β. Sci Rep (2013) 1.00
The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element. Nucleic Acids Res (1998) 1.00
p53 regulates metanephric development. J Am Soc Nephrol (2009) 0.99
Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells. Proc Natl Acad Sci U S A (2012) 0.98
p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53. EMBO J (1998) 0.98
The E7 oncoprotein of human papillomavirus type 16 stabilizes p53 through a mechanism independent of p19(ARF). J Virol (1999) 0.98
Inhibition of p53-mediated growth arrest by overexpression of cyclin-dependent kinases. Mol Cell Biol (1996) 0.97
Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells. Mol Cancer (2010) 0.96
RNA polymerase 1-driven transcription as a mediator of BDNF-induced neurite outgrowth. J Biol Chem (2010) 0.95
Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells. Cancer Biol Ther (2013) 0.95
Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions. Protein Sci (1999) 0.95
Requirement of 3-phosphoinositide-dependent protein kinase-1 for BDNF-mediated neuronal survival. J Neurosci (2008) 0.95
Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors. Mol Cancer Ther (2010) 0.94
Feedback control of p53 translation by REDD1 and mTORC1 limits the p53-dependent DNA damage response. Mol Cell Biol (2011) 0.94
The p53 codon 72 proline allele is endowed with enhanced cell-death inducing potential in cancer cells exposed to hypoxia. Br J Cancer (2007) 0.92
Role of p53 and Rb in ovarian cancer. Adv Exp Med Biol (2008) 0.91
Inactivation of p53 rescues the maintenance of high risk HPV DNA genomes deficient in expression of E6. PLoS Pathog (2013) 0.90
The use of murine-derived fundic organoids in studies of gastric physiology. J Physiol (2015) 0.90
A synthetic interaction screen identifies factors selectively required for proliferation and TERT transcription in p53-deficient human cancer cells. PLoS Genet (2012) 0.88
Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle. Mol Cell Biol (1994) 0.86
Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity. Br J Cancer (2001) 0.86
Telomeric DNA induces p53-dependent reactive oxygen species and protects against oxidative damage. J Dermatol Sci (2009) 0.85
Brain-derived neurotrophic factor induces matrix metalloproteinase 9 expression in neurons via the serum response factor/c-Fos pathway. Mol Cell Biol (2013) 0.84
Beta-catenin/HuR post-transcriptional machinery governs cancer stem cell features in response to hypoxia. PLoS One (2013) 0.84
p28, a first in class peptide inhibitor of cop1 binding to p53. Br J Cancer (2013) 0.84
Tracing the protectors path from the germ line to the genome. Proc Natl Acad Sci U S A (2010) 0.84
Soft tissue sarcomas and p53 mutations. Mol Med (1998) 0.83
Constitutive activation of gene expression by thyroid hormone receptor results from reversal of p53-mediated repression. Mol Cell Biol (1997) 0.83
Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br J Cancer (2003) 0.83
Nucleolar disruption and apoptosis are distinct neuronal responses to etoposide-induced DNA damage. J Neurochem (2011) 0.83
p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle (2012) 0.83
RelA-Induced Interferon Response Negatively Regulates Proliferation. PLoS One (2015) 0.81
Cellular players in the herpes simplex virus dependent apoptosis balancing act. Viruses (2009) 0.79
p53 mutations in human cancers. Science (1991) 31.96
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
The p53 tumour suppressor gene. Nature (1991) 14.49
Definition of a consensus binding site for p53. Nat Genet (1992) 12.76
The p53 proto-oncogene can act as a suppressor of transformation. Cell (1989) 11.67
Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (1990) 11.18
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (1991) 9.21
Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature (1985) 7.07
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (1985) 6.86
Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (1992) 6.73
Identification of p53 as a sequence-specific DNA-binding protein. Science (1991) 6.60
Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol (1988) 6.44
Presence of a potent transcription activating sequence in the p53 protein. Science (1990) 6.38
Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell (1990) 6.37
Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev (1991) 6.30
Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol (1981) 6.02
Tumor suppressor genes. Science (1991) 5.72
Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature (1985) 5.69
Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science (1990) 5.47
Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A (1989) 5.40
p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol (1990) 5.20
Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature (1984) 4.86
Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol (1989) 4.63
Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ (1990) 4.32
Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell (1991) 4.12
Structural aspects of the p53 protein in relation to gene evolution. Oncogene (1990) 3.64
Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell (1991) 3.59
Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A (1991) 3.45
Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science (1992) 3.41
p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature (1987) 3.34
Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci U S A (1990) 3.20
The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen. Cell (1989) 3.01
Precise epitope mapping of the murine transformation-associated protein, p53. EMBO J (1985) 2.98
A single gene and a pseudogene for the cellular tumour antigen p53. Nature (1984) 2.98
Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene (1990) 2.97
Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature (1986) 2.94
p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J (1992) 2.90
Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A (1991) 2.86
Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci U S A (1990) 2.77
Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature (1991) 2.75
Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol (1990) 2.73
Overproduction of p53 antigen makes established cells highly tumorigenic. Nature (1985) 2.72
Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene (1988) 2.71
Mouse p53 inhibits SV40 origin-dependent DNA replication. Nature (1987) 2.71
Genetic mechanisms of tumor suppression by the human p53 gene. Science (1990) 2.68
Immortalization of rat embryo fibroblasts by the cellular p53 oncogene. Oncogene (1988) 2.53
A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene (1992) 2.41
Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol Cell Biol (1991) 2.20
Different tumor-derived p53 mutants exhibit distinct biological activities. Science (1990) 2.20
The MCK enhancer contains a p53 responsive element. Proc Natl Acad Sci U S A (1991) 2.16
A potential transcriptional activation element in the p53 protein. Oncogene (1990) 2.07
Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci U S A (1991) 1.99
The cellular oncogene p53 can be activated by mutagenesis. Nature (1985) 1.99
Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature (1991) 1.99
Adenovirus serotype determines association and localization of the large E1B tumor antigen with cellular tumor antigen p53 in transformed cells. Mol Cell Biol (1985) 1.91
Nuclear localization is essential for the activity of p53 protein. Oncogene (1991) 1.83
Analysis of p53 mutants for transcriptional activity. Mol Cell Biol (1991) 1.73
Energy requirement for degradation of tumor-associated protein p53. Mol Cell Biol (1984) 1.73
When the products of oncogenes and anti-oncogenes meet. Cell (1989) 1.69
Involvement of wild-type p53 in pre-B-cell differentiation in vitro. Proc Natl Acad Sci U S A (1991) 1.65
The structural relationships between 54,000-molecular-weight cellular tumor antigens detected in viral- and nonviral-transformed cells. Virology (1981) 1.64
Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. Mol Cell Biol (1991) 1.61
p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis. Oncogene (1990) 1.59
Maintenance of p53 alterations throughout breast cancer progression. Cancer Res (1991) 1.58
Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J (1992) 1.49
A DNA binding domain is contained in the C-terminus of wild type p53 protein. Nucleic Acids Res (1991) 1.49
Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene (1990) 1.45
Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res (1991) 1.40
Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell (1992) 1.39
Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells. Oncogene (1990) 1.37
p53 mutations: gains or losses? J Cell Biochem (1991) 1.33
Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells. Mol Cell Biol (1991) 1.25
c-myc oncoprotein function. Biochim Biophys Acta (1991) 1.12
Stabilization of the p53 transformation-related protein in mouse fibrosarcoma cell lines: effects of protein sequence and intracellular environment. Mol Cell Biol (1989) 1.12
Frequent p53 mutations in chemically induced murine fibrosarcoma. Oncogene (1991) 1.07
Modulation of immortalizing properties of human papillomavirus type 16 E7 by p53 expression. J Virol (1991) 0.90
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (1991) 9.21
mdm2 expression is induced by wild type p53 activity. EMBO J (1993) 8.01
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (1985) 6.86
Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol (1988) 6.44
Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell (1990) 6.37
Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A (1989) 5.40
Binding and modulation of p53 by p300/CBP coactivators. Nature (1997) 5.12
ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev (2001) 4.06
Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci U S A (2000) 3.74
Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature (1999) 3.50
Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A (1991) 3.45
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev (1995) 3.40
Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol (1983) 3.39
p53 in growth control and neoplasia. Biochim Biophys Acta (1996) 3.19
Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J (1985) 3.18
p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol (1985) 3.13
Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene (1993) 3.08
Functional interaction between E2F-4 and p130: evidence for distinct mechanisms underlying growth suppression by different retinoblastoma protein family members. Genes Dev (1995) 3.02
A single gene and a pseudogene for the cellular tumour antigen p53. Nature (1984) 2.98
Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature (1986) 2.94
Analysis of the gene coding for the murine cellular tumour antigen p53. EMBO J (1984) 2.94
Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem (2001) 2.93
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med (1998) 2.91
Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev (1994) 2.88
Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci U S A (1999) 2.87
p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ (2009) 2.80
Differential affinities of simian virus 40 large tumor antigen for DNA. Proc Natl Acad Sci U S A (1980) 2.75
Overproduction of p53 antigen makes established cells highly tumorigenic. Nature (1985) 2.72
Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene (1988) 2.71
Non-visualization of the cavum septi pellucidi is not synonymous with agenesis of the corpus callosum. Ultrasound Obstet Gynecol (2012) 2.65
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J (1999) 2.64
Localization of gene for human p53 tumour antigen to band 17p13. Nature (1986) 2.56
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene (1999) 2.43
Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell (2000) 2.30
p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol (1993) 2.27
TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ (2005) 2.25
The subcellular localization of E2F-4 is cell-cycle dependent. Proc Natl Acad Sci U S A (1997) 2.24
A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res (1995) 2.23
Different tumor-derived p53 mutants exhibit distinct biological activities. Science (1990) 2.20
The 5' region of the p53 gene: evolutionary conservation and evidence for a negative regulatory element. EMBO J (1985) 2.17
Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J (1996) 2.12
Properties of permissive monkey cells transformed by UV-irradiated simian virus 40. J Virol (1977) 2.03
MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol (1999) 2.00
A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol (1996) 1.98
Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature (1996) 1.98
Oligomerization of oncoprotein p53. J Virol (1988) 1.98
SV40 large tumor antigen can regulate some cellular transcripts in a positive fashion. Cell (1982) 1.85
Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J (1996) 1.82
Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol Cell Biol (1982) 1.82
Transcription regulation by mutant p53. Oncogene (2007) 1.78
Smoking cessation and weight gain. J Consult Clin Psychol (1986) 1.77
Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes. EMBO J (1993) 1.77
Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene (1993) 1.77
E2F1 regulates autophagy and the transcription of autophagy genes. Oncogene (2008) 1.75
Different forms of simian virus 40 large tumor antigen varying in their affinities for DNA. J Virol (1982) 1.72
Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J (2001) 1.69
Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene (2000) 1.67
Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. Proc Natl Acad Sci U S A (1983) 1.65
Physical and functional interaction between p53 and the Werner's syndrome protein. J Biol Chem (1999) 1.64
The structural relationships between 54,000-molecular-weight cellular tumor antigens detected in viral- and nonviral-transformed cells. Virology (1981) 1.64
Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO J (1994) 1.64
Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J (1999) 1.63
Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. Mol Cell Biol (1991) 1.61
Down-regulation of beta-catenin by activated p53. Mol Cell Biol (2001) 1.60
Ketamine enhances local anesthetic and analgesic effects of bupivacaine by peripheral mechanism: a study in postoperative patients. Neurosci Lett (1996) 1.56
Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene (1999) 1.56
Complementation by wild-type p53 of interleukin-6 effects on M1 cells: induction of cell cycle exit and cooperativity with c-myc suppression. Mol Cell Biol (1993) 1.56
Analysis of recombinant DNA clones specific for the murine p53 cellular tumor antigen. EMBO J (1983) 1.55
The Mdm2 oncoprotein interacts with the cell fate regulator Numb. Mol Cell Biol (1998) 1.53
Inhibition of cell growth mediated by plasmids encoding p53 anti-sense. Oncogene (1987) 1.52
Nuclear membrane protein LAP2beta mediates transcriptional repression alone and together with its binding partner GCL (germ-cell-less). J Cell Sci (2001) 1.51
The cytoplasmic domain of adherens-type junctions. Cell Motil Cytoskeleton (1991) 1.51
Regulation of the retinoblastoma protein-related protein p107 by G1 cyclin-associated kinases. Proc Natl Acad Sci U S A (1996) 1.51
The p53 cellular tumor antigen: gene structure, expression and protein properties. Biochim Biophys Acta (1985) 1.50
Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J (1992) 1.49
Expression analysis using DNA microarrays demonstrates that E2F-1 up-regulates expression of DNA replication genes including replication protein A2. Oncogene (2001) 1.48
Broad spectrum pan-cadherin antibodies, reactive with the C-terminal 24 amino acid residues of N-cadherin. J Cell Sci (1990) 1.45
SIAH-1 promotes apoptosis and tumor suppression through a network involving the regulation of protein folding, unfolding, and trafficking: identification of common effectors with p53 and p21(Waf1). Proc Natl Acad Sci U S A (1999) 1.44
Biochemical properties and biological effects of p53. Curr Opin Genet Dev (1995) 1.44
Identification of p53 target genes through immune selection of genomic DNA: the cyclin G gene contains two distinct p53 binding sites. Oncogene (1995) 1.44
Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression. Nat Med (1998) 1.44
Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem (2000) 1.43
Mdm2: the ups and downs. Mol Med (1999) 1.43
p53 and apoptosis. Semin Cancer Biol (1998) 1.43
Tissue-specific inactivation of p53 tumor suppression in the mouse. Genes Dev (1996) 1.42
Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther (2010) 1.41
Activation of the human homologue of the Drosophila sina gene in apoptosis and tumor suppression. Proc Natl Acad Sci U S A (1996) 1.40
Loss of p53 function through PAX-mediated transcriptional repression. EMBO J (1995) 1.38
Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells. Oncogene (1990) 1.37
Activated Ha-ras can cooperate with defective simian virus 40 in the transformation of nonestablished rat embryo fibroblasts. J Virol (1987) 1.36
p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene (1995) 1.36
Degradation of the tumor suppressor protein p53 by the ubiquitin-mediated proteolytic system requires a novel species of ubiquitin-carrier protein, E2. J Biol Chem (1994) 1.35
p53 mutations: gains or losses? J Cell Biochem (1991) 1.33
Siah-1 binds and regulates the function of Numb. Proc Natl Acad Sci U S A (2001) 1.33
p53; from inductive signal to cellular effect. Curr Opin Genet Dev (1997) 1.32